Status:
UNKNOWN
Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Liver Cirrhosis
Esophageal and Gastric Varices
Eligibility:
All Genders
Brief Summary
To observe and access the Effects and safety of terlipressin or high dose somatostatin/octreotide when usual dose somatostatin/octreotide fail to achieve hemostasis in patients with acute variceal ble...
Detailed Description
The prognosis information of the patients with acute variceal bleeding will be collected, including hemostasis rate, early rebleeding rate, mortality, complications, severity adverse events, economic ...
Eligibility Criteria
Inclusion
- Cirrhosis patients admitted to Emergency Department because of acute variceal bleeding
Exclusion
- No signs of variceal bleeding are found by endoscopy or portal hypertensive gastropathy is responsible for the bleeding
- Patients undergo endoscopy after 72h from the beginning of acute variceal bleeding
- Patients with hepatorenal syndrome
- Patients with ischemia organic cardiopathy (including myocardial infarction or unstable angina pectoris) or myocardial ischemia indicated by ECG in the past 6 months
- Patients allergic to/with contraindications of vasoactive drugs
Key Trial Info
Start Date :
February 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2016
Estimated Enrollment :
1320 Patients enrolled
Trial Details
Trial ID
NCT02311608
Start Date
February 1 2014
End Date
June 1 2016
Last Update
December 8 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital
Shanghai, Shanghai Municipality, China, 200032